Nasdaq

TC BioPharm Approves Key Resolutions to Enhance Strategic Flexibility

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
Seeking Alpha

TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D

EDINBURGH, Scotland, Dec. 18, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC (TCBP) ("TC BioPharm" or the "Company") a clinical stage biotechnology company developing platform allogeneic gamma-delta ...
Nasdaq

TC Biopharm shareholders approve 25% stock dividend

TC BioPharm (TCBP) announced that shareholders have formally approved the recently announced 25% stock dividend. TC BioPharm declared that last week’s proposed special stock dividend was formally ...
Seeking Alpha

TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico

EDINBURGH, Scotland, April 19, 2023 (GLOBE NEWSWIRE) -- TC BioPharm (Holdings) PLC (TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, ...
AOL

EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend

On Wednesday, TC BioPharm (Holdings) PLC (NASDAQ:TCBP) announced that its Board of Directors approved a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, ...
Business Insider

TC Biopharm advances negotiations with acquisition candidates

TC BioPharm (TCBP) has advanced negotiations with both of its previously aforementioned acquisition candidates. This past spring TCBP announced the execution of non-binding letters of intent as part ...
Business Insider

TC Biopharm price target lowered to $3 from $7 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on TC Biopharm (TCBP) to $3 from $7 and keeps a Buy rating on the shares. The firm updated its model to reflect launch timing, market trends, and ...
Investing

TC BioPharm to start preclinical studies on monkeypox therapy

EDINBURGH - TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company, announced today its plans to initiate Proof of Concept preclinical studies for its leading therapeutic ...
Business Wire

CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of ...
NBC4 Columbus

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer ...
The Motley Fool

Tc Biopharm (Holdings) Plc

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.